ASX Share rice
Wed 12 Aug 2020 - 04:17:am (Sydney)

1AD Share Price

ADALTA LIMITED1ADPharmaceuticals, Biotechnology & Life Sciences

1AD Company Information

Name:

AdAlta Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

2 Park Drive Bundoora VIC Australia 3083

Phone:

61 3 9479 5159

CEO, MD & Director:

Dr. Timothy Charles Oldham

Chief Operating Officer:

Dr. Dallas Hartman

Chief Scientific Advisor & Chief Scientific Officer:

Prof. Michael Foley Ph.D.

Company Sec.:

Mr. Cameron Jones

Company Overview:

AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with Excellerate Bioscience to advance the development of its i-body pipeline. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.

1AD Share Price Information

Shares Issued:

163.95M

Market Capitalisation:

$18.03M

Revenue (TTM):

$3.91M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$-0.05

Profit Margin:

-2.1229

Operating Margin (TTM):

$-2.16

Return On Assets (TTM):

$-0.96

Return On Equity (TTM):

$-1.99

Quarterly Revenue Growth (YOY):

10.591

Gross Profit(TTM):

$-3,996,306

Diluted Earnings Per Share (TTM):

$-0.058

1AD CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-170,602

Change To Liabilities:

$1.45M

Total Cashflow From Investing Activities:

$-170,602

Net Income:

$-5,918,193

Total Cash From Operating Activities:

$-5,816,085

Depreciation:

$32.50K

Change To Account Receivables:

$-1,483,140

Sale Purchase Of Stock:

$-716,091

Capital Expenditures:

$170.60K

1AD Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-5,918,193

Net Income:

$-5,918,193

Gross Profit:

$-7,353,660

Operating Income:

$-9,527,855

Other Operating Expenses:

$726.11K

Total Revenue:

$3.54M

Total Operating Expenses:

$2.17M

Cost Of Revenue:

$7.35M

1AD Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$1.82M

Total Stockholder Equity:

$7.49M

Other Current Liabilities:

$18.80K

Total Assets:

$9.31M

Common Stock:

$26.53M

Other Current Assets:

$-1

Retained Earnings:

$-19,591,956

Other Assets:

$2.60K

Cash:

$5.56M

Total Current Liabilities:

$1.82M

Property - Plant & Equipment:

$138.11K

Net Tangible Assets:

$7.49M

Long-Term Investments:

$2.60K

Total Current Assets:

$9.17M

Net Receivables:

$3.58M

Short-Term Investments:

$140.71K

Accounts Payable:

$1.51M

Non Currrent Assets (Other):

$2.60K

Short-Term Investments:

$140.71

Non Current Liabilities Total:

$0

1AD Share Price History

1AD News

19 Oct, 2019
Every investor in AdAlta Limited (ASX:1AD) should be aware of the most powerful shareholder groups. Insiders often own...
09 Oct, 2019
MELBOURNE, Australia, Oct. 9, 2019 /PRNewswire/ -- The Board of AdAlta Limited (1AD.AX), is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director. Dr Oldham has extensive skills and expertise over his career in the industry in strategy and portfolio building, biologic therapies development and pipeline commercialisation.
16 Sep, 2019
AdAlta secures commercial agreement for its i-body platform with global medical technology and diagnostics firm, GE Healthcare. Under the licensing deal, the two companies will develop i-bodies for diagnostic imaging. AdAlta will screen its novel i-body library on a number of targets in order to identify i-bodies that GE can use as imaging agents, starting with Granzyme B.
05 Sep, 2019
Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of AdAlta Limited...